Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: A case report

BMC Research Notes

Volumn 6, Issue 1, 2013, Pages

  Rossing, Henrik H ^a   Grauslund, Morten ^a   Urbanska, Edyta M ^a   Melchior, Linea C ^a   Rask, Charlotte K ^a   Costa, Junia C ^a   Skov, Birgit G ^a   Sørensen, Jens Benn ^a   Santoni Rugiu, Eric ^a  

^a University of Copenhagen   (Denmark)

Author keywords

Acquired resistance; Crizotinib; EGFR mutation; EML4 ALK; KRAS mutation; Lung cancer

Indexed keywords

RATTUS;

ANAPLASTIC LYMPHOMA KINASE; ANTINEOPLASTIC AGENT; CRIZOTINIB; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; KRAS PROTEIN, HUMAN; ONCOPROTEIN; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; RAS PROTEIN;

ADENOCARCINOMA; ARTICLE; CANCER STAGING; CASE REPORT; DRUG RESISTANCE; FATALITY; GENETICS; HUMAN; LUNG ADENOCARCINOMA; LUNG TUMOR; MALE; METASTASIS; MIDDLE AGED; MUTATION; PATHOLOGY;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; FATAL OUTCOME; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; NEOPLASM STAGING; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; PYRAZOLES; PYRIDINES; RAS PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84888145792     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-6-489     Document Type: Article

References (22)

1. European cancer mortality predictions for the year 2012. Malvezzi M, Bertuccio P, Levi F, La Vecchia C, Negri E, Ann Oncol 2012 23 1044 1052 10.1093/annonc/mds024 22373539
2. ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development. Scagliotti G, Stahel RA, Rosell R, Thatcher N, Soria JC, Eur J Cancer 2012 48 961 973 10.1016/j.ejca.2012.02.001 22397764
3. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, et al. Nature 2007 448 561 566 10.1038/nature05945 17625570 (Pubitemid 47206930)
4. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS, Solomon B, Stubbs H, Admane S, McDermott U, et al. J Clin Oncol 2009 27 4247 4253 10.1200/JCO.2009.22.6993 19667264
5. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Janne PA, Costa DB, et al. N Engl J Med 2010 363 1693 1703 10.1056/NEJMoa1006448 20979469
6. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Shaw AT, Yeap BY, Solomon BJ, Riely GJ, Gainor J, Engelman JA, Shapiro GI, Costa DB, Ou SHI, Butaney M, et al. Lancet Oncol 2011 12 1004 1012 10.1016/S1470-2045(11)70232-7 21933749
7. Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer. Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, et al. N Engl J Med 2013 368 2385 2394 10.1056/NEJMoa1214886 23724913
8. EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations. Thunnissen E, Bubendorf L, Dietel M, Elmberger G, Kerr K, Lopez-Rios F, Moch H, Olszewski W, Pauwels P, Penault-Llorca F, Rossi G, Virchows Arch 2012 461 245 257 10.1007/s00428-012-1281-4 22825000
9. Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers. Katayama R, Shaw AT, Khan TM, Mino-Kenudson M, Solomon BJ, Halmos B, Jessop NA, Wain JC, Yeo AT, Benes C, et al. Sci Transl Med 2012 4 120ra17 22277784
10. Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants. Heuckmann JM, Balke-Want H, Malchers F, Peifer M, Sos ML, Koker M, Meder L, Lovly CM, Heukamp LC, Pao W, et al. Clin Cancer Res 2012 18 4682 4690 10.1158/1078-0432.CCR-11-3260 22912387
11. Multiplexed gene expression and fusion transcript analysis to detect ALK fusions in lung cancer. Lira ME, Kim TM, Huang D, Deng S, Koh Y, Jang B, Go H, Lee SH, Chung DH, Kim WH, et al. J Mol Diagn 2013 15 51 61 10.1016/j.jmoldx. 2012.08.006 23246132
12. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1683 patients with non-small cell lung cancer. Gainor JF, Varghese AM, Ou SH, Kabraji S, Awad MM, Katayama R, Pawlak A, Mino-Kenudson M, Yeap BY, Riely GJ, et al. Clin Cancer Res 2013 19 4273 4281 10.1158/1078-0432. CCR-13-0318 23729361
13. ALK Inhibitors, a Pharmaceutical Perspective. Ardini E, Galvani A, Front Oncol 2012 2 17 22655263
14. Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer. Tanizaki J, Okamoto I, Okabe T, Sakai K, Tanaka K, Hayashi H, Kaneda H, Takezawa K, Kuwata K, Yamaguchi H, et al. Clin Cancer Res 2012 18 6219 6226 10.1158/1078-0432.CCR- 12-0392 22843788
15. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Doebele RC, Pilling AB, Aisner DL, Kutateladze TG, Le AT, Weickhardt AJ, Kondo KL, Linderman DJ, Heasley LE, Franklin WA, et al. Clin Cancer Res 2012 18 1472 1482 10.1158/1078-0432.CCR-11- 2906 22235099
16. Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression. Zhang X, Zhang S, Yang X, Yang J, Zhou Q, Yin L, An S, Lin J, Chen S, Xie Z, et al. Mol Cancer 2010 9 188 10.1186/1476-4598-9-188 20624322
17. Good response to gefitinib in lung adenocarcinoma harboring coexisting EML4-ALK fusion gene and EGFR mutation. Kuo YW, Wu SG, Ho CC, Shih JY, J Thorac Oncol 2010 5 2039 2040 10.1097/JTO.0b013e3181f43274 21102267
18. Lung adenocarcinoma with concurrent exon 19 EGFR mutation and ALK rearrangement responding to erlotinib. Popat S, de Araujo Vieira A, Min T, Swansbury J, Dainton M, Wotherspoon A, Lim E, Nicholson AG, O'Brien ME, J Thorac Oncol 2011 6 1962 1963 10.1097/JTO.0b013e31822eec5e 22005476
19. EGFR and EML4-ALK gene mutations in NSCLC: a case report of erlotinib-resistant patient with both concomitant mutations. Tiseo M, Gelsomino F, Boggiani D, Bortesi B, Bartolotti M, Bozzetti C, Sammarelli G, Thai E, Ardizzoni A, Lung Cancer 2011 71 241 243 10.1016/j.lungcan.2010.11.014 21168933
20. A case of lung adenocarcinoma harboring EGFR mutation and EML4-ALK fusion gene. Tanaka H, Hayashi A, Morimoto T, Taima K, Tanaka Y, Shimada M, Kurose A, Takanashi S, Okumura K, BMC Cancer 2012 12 558 10.1186/1471-2407-12-558 23181703
21. Abdominal lymph node metastasis in patients with non-small-cell lung cancer as shown by PET/CT. Karyagar S, Koc ZP, Karyagar SS, Ozturk I, Cengiz E, Sayc Y, Balci TA, Clin Nucl Med 2013 38 691 694 10.1097/RLU.0b013e31829b9bed 23816947
22. Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations. De Pas T, Toffalorio F, Manzotti M, Fumagalli C, Spitaleri G, Catania C, Delmonte A, Giovannini M, Spaggiari L, de Braud F, Barberis M, J Thorac Oncol 2011 6 1895 1901 10.1097/JTO.0b013e318227e8c6 21841502